Today 19 March 2014, the National Institute for Health and Care Excellence (NICE) is holding its final committee meeting to appraise advanced prostate cancer drug enzalutamide for use on the NHS in England and Wales for men who have already had chemotherapy. Since January Prostate Cancer UK has been spearheading a campaign against proposed restrictions in access to the life-extending treatment which have sparked outrage among thousands affected by the disease across the country.

Read more